# Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms

> **NCT05162833** · NA · COMPLETED · sponsor: **Theranova, L.L.C.** · enrollment: 3 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DEVICE:** TheraNova Neuromodulation Device

## Key facts

- **NCT ID:** NCT05162833
- **Lead sponsor:** Theranova, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-20
- **Primary completion:** 2023-12-08
- **Final completion:** 2023-12-08
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162833, "Evaluation of the TheraNova Neuromodulation System to Provide Durable Relief of Overactive Bladder Symptoms". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05162833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*